Older Coverage
stories 541–600 of 705
IPOIPO odds: 18.5%
Apple's Trade-Secrets Suit Threatens OpenAI's IPO
Apple's trade-secrets lawsuit against OpenAI, alleging its hardware chief directed former Apple staff to bring 'actual parts' to interviews, has already cut Wall Street's odds of a 2026 OpenAI IPO from roughly 22% to 18.5%.
Public Markets Are Stress-Testing the AI Infra Trade
IPO
Public Markets Are Stress-Testing the AI Infra Trade
Value Add Pulse analysis: Csquare's soft debut, Standard Nuclear's downsized listing, SpaceX's Starship setback and Alphabet's Gemini-delay selloff landed within 48 hours, showing markets are pricing AI-infra execution risk in real time.
IPO Party Faces Down Volatility, Sinking SpaceX
IPO
IPO Party Faces Down Volatility, Sinking SpaceX
Newcomer's weekly analysis asks whether 2026's red-hot IPO window can survive SpaceX's post-listing stock collapse and a broader volatility spike, with several AI-adjacent companies still queued to list this year.
12 New S-1 Filings Show a Micro-Cap Biotech Wave
IPO
12 New S-1 Filings Show a Micro-Cap Biotech Wave
A dozen new SEC S-1 and S-1/A filings this week, dominated by small biotech and biopharma names, show a steady drip of micro-cap public offerings continuing well below the AI-mega-cap headlines dominating the IPO conversation.
SpaceX Falls Further as Starship Test Flight Aborted
IPO
SpaceX Falls Further as Starship Test Flight Aborted
SpaceX shares fell further in premarket trading after a Starship test flight was aborted when several engines failed to start, adding a fresh operational setback on top of the stock's already-below-issue-price slide.
Seven Companies File S-1s in a Single Week
IPO
Seven Companies File S-1s in a Single Week
Seven companies spanning biotech, fintech, AI and battery materials filed IPO registration paperwork with the SEC within days of each other, a broad-based cluster that extends the sustained widening of 2026's listing pipeline.
Brookfield's Csquare Prices Below Range, Opens Down
IPO$3.24B valuation
Brookfield's Csquare Prices Below Range, Opens Down
Brookfield-backed data center provider Csquare priced its IPO at $21 a share, below its marketed range, and opened down about 3% at $20.90, a soft debut that signals investor caution toward new data-center listings despite AI-driven demand.
The IPO Pipeline Is Quietly Getting Longer
IPO
The IPO Pipeline Is Quietly Getting Longer
Value Add Pulse analysis: the mix of filings landing in mid-July 2026 -- SPAC revival, sustained biotech S-1s, mega-cap AI IPO prep and a wobbling SpaceX debut -- shows a pipeline broadening in kind, not just size.
Standard Nuclear Debuts on NYSE After 58% IPO Cut
IPO$150M raise, $2.4B cap
Standard Nuclear Debuts on NYSE After 58% IPO Cut
TRISO fuel maker Standard Nuclear began trading on the NYSE under ticker STDN after slashing its IPO size by 58% to $150 million on the eve of pricing, a live early test of how public markets value pre-revenue nuclear-fuel suppliers.
Brookfield-Backed Csquare Slips in $3.24B NYSE Debut
IPO$1.05B raised
Brookfield-Backed Csquare Slips in $3.24B NYSE Debut
Data-center operator Csquare priced its IPO $2 below range at $21 a share, raising $1.05 billion, and slipped further on its NYSE debut -- a soft landing for the year's newest bet on AI-driven data-center demand.
SpaceX Stock Slide Costs Musk Trillionaire Status
IPOBelow $135 IPO price
SpaceX Stock Slide Costs Musk Trillionaire Status
SpaceX shares fell below their $135 IPO price for the first time, erasing enough of Elon Musk's paper wealth to end his trillionaire status.
Standard Nuclear Slashes IPO Size by 58% Ahead of Pricing
IPO$150M raise, ~$2.4B cap
Standard Nuclear Slashes IPO Size by 58% Ahead of Pricing
TRISO fuel maker Standard Nuclear cut its IPO to $150 million from a planned $355.88 million on the eve of pricing, a rare down-sizing that signals soft investor demand even inside the hot nuclear-fuel supply-chain theme.
SpaceX Shares Slip Below Their $135 IPO Price
IPOBelow $135/share
SpaceX Shares Slip Below Their $135 IPO Price
SpaceX stock traded below its $135 IPO price for the first time, a notable early test for one of the most anticipated public listings in recent market history.
Jaguar Health, Vogenx Join a Growing Biotech S-1 Queue
IPO
Jaguar Health, Vogenx Join a Growing Biotech S-1 Queue
Jaguar Health and Vogenx both filed S-1 paperwork with the SEC, adding to a biotech IPO queue that's grown steadily through 2026 as public-market appetite for clinical-stage listings recovers.
SPAC and Fintech S-1 Filings Surge in a Single Day
IPO
SPAC and Fintech S-1 Filings Surge in a Single Day
Banzai International, FreeCast, authID and Churchill Capital Corp XIII all filed IPO or SPAC-related paperwork with the SEC the same day, a notable cluster in an otherwise quiet software-listing environment.
Anthropic Moves Closer to a Mega-IPO
IPO
Anthropic Moves Closer to a Mega-IPO
Anthropic is moving closer to a public listing, with bankers reportedly lining up investor meetings, a step that would make it one of the largest AI IPOs alongside OpenAI's own expected debut.
Stripe's Deal Pace Accelerates With Reported $53B PayPal Bet
IPO~$53B reported deal
Stripe's Deal Pace Accelerates With Reported $53B PayPal Bet
Stripe's acquisition pace has accelerated meaningfully, with nothing rivaling its reported interest in a roughly $53 billion PayPal-related deal, a scale of ambition unusual for a still-private fintech giant.
Standard Nuclear Amends Its NYSE IPO Filing
IPO
Standard Nuclear Amends Its NYSE IPO Filing
Standard Nuclear filed an amended S-1/A refining terms for its planned NYSE listing to fund its small modular reactor buildout, a sign underwriters are finalizing roadshow pricing.
The SPAC Pipeline Is Quietly Filling Back Up
IPO
The SPAC Pipeline Is Quietly Filling Back Up
Two SPAC vehicles, Crestone Strategic Capital and Material Resource Acquisition Corp, both progressed toward listing this week, a quiet sign the blank-check market is testing itself again.
Two New Biotech IPO Filings Land in One Week
IPO2 S-1s, same week
Two New Biotech IPO Filings Land in One Week
Braveheart Bio and Attovia Therapeutics both filed S-1s the same week, adding two names to 2026's biotech IPO pipeline amid the strongest H1 biotech venture funding since 2022.
Anthropic's $965B Mark Meets the Physical-Infra IPO
IPO$965B valuation, $47B revenue
Anthropic's $965B Mark Meets the Physical-Infra IPO
Anthropic's confidential S-1 and $965 billion valuation sit against a backdrop where this year's actual IPO winners -- SK Hynix, Csquare, Standard Nuclear -- have all been physical infrastructure, not software-first AI labs.
The Software IPO Drought Behind 2026's Infra Boom
IPOInfra IPOs vs thin software pipeline
The Software IPO Drought Behind 2026's Infra Boom
SK Hynix, Csquare, Standard Nuclear and Meta's $50B Louisiana buildout keep winning capital while pure application-layer software IPOs stay scarce -- a gap that's now wide enough to be the real 2026 IPO story.
Plaid's IPO Chatter Is a Fintech Market Signal
IPO$8B considered valuation
Plaid's IPO Chatter Is a Fintech Market Signal
Plaid is weighing a US IPO after reaching an $8 billion valuation, still well below its 2021 peak of $13.4 billion, a signal of how selectively fintech valuations are recovering as physical AI infrastructure dominates IPO attention.
DeepSeek in Talks to Raise $1.5B, Then IPO
IPO$1.5B raise
DeepSeek in Talks to Raise $1.5B, Then IPO
DeepSeek is reportedly in talks to raise $1.5 billion in private funding as a step toward an eventual IPO, following Goldman Sachs naming it a preferred Chinese AI model.
Quantum Corp Files S-1 for a Fresh Public Listing
IPO
Quantum Corp Files S-1 for a Fresh Public Listing
Legacy data-storage company Quantum Corp filed a new S-1 with the SEC, a notable re-listing move as AI-driven data growth renews demand for storage infrastructure.
The SPAC Market's Quiet 2026 Comeback
IPO$9.8B Q2 2026
The SPAC Market's Quiet 2026 Comeback
SPACs priced 55 IPOs raising $9.8 billion in Q2 2026 alone, and a fresh wave of merger announcements -- from healthcare to energy to biotech -- shows the vehicle finding real footing again after its 2022-era collapse.
Biotech's IPO Window: Open, But Only for the Strongest Pipelines
IPO$45M target
Biotech's IPO Window: Open, But Only for the Strongest Pipelines
Tarsier Pharma's ~$45 million NYSE American debut shows biotech's IPO window remains open in 2026 -- but only for companies with genuinely differentiated, late-stage pipelines, not broad speculative interest.
SK Hynix's Pop Is a Preview of the OpenAI-Anthropic IPO Fight
IPO$2T+ combined
SK Hynix's Pop Is a Preview of the OpenAI-Anthropic IPO Fight
SK Hynix's 13% first-day pop is the freshest data point ahead of a much bigger test: OpenAI and Anthropic are both racing toward IPOs that could value the two labs at a combined $2 trillion or more.
Chinese Humanoid Robotics Startups Rush Toward IPOs
IPO$2.21B (LimX)
Chinese Humanoid Robotics Startups Rush Toward IPOs
LimX Dynamics and Unitree are rushing toward IPOs as Chinese humanoid-robotics companies treat a public listing as close to mandatory, following LimX's $200 million pre-IPO round at a $2.21 billion valuation.
Standard Nuclear Files for NYSE IPO to Fund SMR Buildout
IPO$356M target
Standard Nuclear Files for NYSE IPO to Fund SMR Buildout
Standard Nuclear plans to list on the NYSE this week, offering 18.25 million shares at $18-$21 to raise roughly $356 million at a $3.3 billion valuation, funding its small modular reactor buildout.
Data-Center Operator Csquare Files for $1.25B NYSE IPO
IPO$1.25B target
Data-Center Operator Csquare Files for $1.25B NYSE IPO
Csquare, a data-center operator, is set to list on the NYSE this week offering 50 million shares at $23-$27, targeting roughly $1.25 billion at the midpoint -- one of two infrastructure IPOs headlining this week's calendar.
SK Hynix Begins Regular Nasdaq Trading as Ticker Flips to SKHY
IPO$26.5B raised
SK Hynix Begins Regular Nasdaq Trading as Ticker Flips to SKHY
SK Hynix's ADRs began trading under their permanent ticker SKHY on Monday, days after the memory-chip giant's $26.5 billion Nasdaq debut -- the largest-ever US listing by a non-American company -- popped 13% on its first day.
Why 2026's IPO Boom Keeps Rewarding Infrastructure First
IPO
Why 2026's IPO Boom Keeps Rewarding Infrastructure First
Value Add Pulse analysis: the largest, best-received 2026 IPOs and pre-IPO windfalls have overwhelmingly gone to the physical and financial infrastructure underneath AI, not to application-layer companies riding on top of it.
James Murdoch's SpaceX Bet Nets $7.5 Billion
IPO$7.5B windfall (est.)
James Murdoch's SpaceX Bet Nets $7.5 Billion
James Murdoch's roughly $120 million of pre-IPO SpaceX stock, bought in 2019 and 2020 via Lupa Systems, could now be worth as much as $7.4 billion following SpaceX's public listing, Pitchbook analysis shows.
Why the 2026 IPO Boom Is About to Broaden Beyond AI
IPO
Why the 2026 IPO Boom Is About to Broaden Beyond AI
US IPO proceeds hit roughly $115.6 billion in H1 2026 on a handful of AI and chip mega-deals, but Fortune reports strategists expect H2 to broaden into manufacturing, defense and energy listings.
SK Hynix Jumps 13% in Record $26.5B Nasdaq Debut
IPO$26.5B
SK Hynix Jumps 13% in Record $26.5B Nasdaq Debut
SK Hynix's ADRs priced at $149 and closed up nearly 13% on their Nasdaq debut, raising $26.5 billion in the largest first-time U.S. listing by a foreign company on record.
SK Hynix Raises $26.5B in Largest-Ever Foreign US IPO
IPO$26.5B IPO
SK Hynix Raises $26.5B in Largest-Ever Foreign US IPO
SK Hynix priced 177.9 million ADRs at $149 each to raise $26.5 billion on Nasdaq, topping Alibaba's 2014 debut as the largest US listing ever by a foreign company, and popped 14% at the open.
Holtec Nuclear Files for Nasdaq IPO to Fund SMR Buildout
IPO
Holtec Nuclear Files for Nasdaq IPO to Fund SMR Buildout
Holtec Nuclear Corp, which owns and is restarting Michigan's 800 MW Palisades plant and leads spent-fuel storage, filed for a Nasdaq listing to fund its SMR-300 small modular reactor rollout.
Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill
IPO
Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill
Apnimed, a Shionogi-backed clinical-stage biotech, filed for a Nasdaq IPO under ticker APMD as its lead drug candidate Oxnimbi -- the first investigational oral pill for obstructive sleep apnea -- awaits an FDA decision expected in Q1 2027.
AI Infrastructure Firm Corvex Goes Public via Movano Reverse Merger
IPO
AI Infrastructure Firm Corvex Goes Public via Movano Reverse Merger
AI infrastructure company Corvex is going public through a reverse merger with public shell Movano Inc., with Corvex shareholders projected to own about 94.8% of the combined entity.
Healthcare Triangle Registers $50M Equity Line With Hudson
IPO
Healthcare Triangle Registers $50M Equity Line With Hudson
Healthcare Triangle filed an S-1 registering 28 million shares for resale by Hudson Global Ventures, giving the Nasdaq-listed healthcare-cloud company access to up to $50 million in gross proceeds through an equity line of credit.
Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO
IPO$180M+ partnership payments
Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO
Scribe Therapeutics, the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, amended its S-1 to list on Nasdaq under ticker SCTX, backed by more than $180 million in Sanofi and Eli Lilly partnership payments.
Laser Photonics Files Fresh S-1 for Warrant Share Resale
IPO
Laser Photonics Files Fresh S-1 for Warrant Share Resale
Laser Photonics Corp, a Nasdaq-listed industrial laser-cleaning maker, filed its third S-1 of 2026 on July 10, continuing a pattern of registering shares tied to inducement and placement-agent warrants.
Decoy Therapeutics Files S-1 Amid $21M Milestone-Based PIPE
IPO~$3.5M base + up to $21M contingent
Decoy Therapeutics Files S-1 Amid $21M Milestone-Based PIPE
Decoy Therapeutics filed its second S-1 in a month tied to a private placement that could deliver up to $21 million in milestone-based warrant proceeds contingent on trial results and shareholder approval.
iPower Files New S-1 as It Manages an Existing Nasdaq Listing
IPO
iPower Files New S-1 as It Manages an Existing Nasdaq Listing
iPower Inc, a Rancho Cucamonga-based consumer products company trading under "IPW," filed a new Form S-1 on July 10, its second such registration of 2026 after an earlier S-1/A in January.
Avalanche Treasury Files S-1 After Stock Crashed 73% Post-Debut
IPOGoing-concern warning
Avalanche Treasury Files S-1 After Stock Crashed 73% Post-Debut
Avalanche Treasury Corp, whose AVAT stock has fallen 73% since its Nasdaq debut via SPAC merger, filed a new S-1 as it flags crypto losses and warns it may not survive without additional financing.
Universal Safety Products Files S-1 Amid Warned Net Loss
IPO
Universal Safety Products Files S-1 Amid Warned Net Loss
Universal Safety Products filed a Form S-1 for up to 10.6 million shares on the same day it warned of a substantial sales and gross-profit decline and an expected net loss for the year ended March 31, 2026.
NeuroSpectrum Insights Amends IPO Filing a Fifth Time
IPO
NeuroSpectrum Insights Amends IPO Filing a Fifth Time
NeuroSpectrum Insights, formerly Autism Diagnostic Technologies, filed its fifth S-1/A amendment since January, the latest step in a lengthy SEC review process for its planned public offering.
Nexchip Prices $890M Hong Kong IPO at Top of Range
IPO$890 million raised
Nexchip Prices $890M Hong Kong IPO at Top of Range
Chinese chipmaker Nexchip Semiconductor priced its Hong Kong listing at HK$32.30 per share, the top of its range, raising roughly HK$6.98 billion ($890 million) as it pursues a dual Shanghai-Hong Kong listing amid a booming HK IPO market.
GridAI Technologies Amends S-1 as Energy-AI Pivot Continues
IPO
GridAI Technologies Amends S-1 as Energy-AI Pivot Continues
GridAI Technologies, formerly biopharma company Entero Therapeutics, filed an amended S-1 registering shares tied to recent PIPE financings as it repositions around energy-orchestration and grid-optimization software for AI datacenters.
Zapata Quantum's S-1/A Shows Going-Concern Risk Persists
IPO
Zapata Quantum's S-1/A Shows Going-Concern Risk Persists
Zapata Quantum filed an amended S-1/A registering 56.8 million shares for resale, disclosing ongoing losses and going-concern risk despite a recent $15 million Series D and a return to current SEC reporting status.
Mitesco Files S-1 to Register Equity Line Shares
IPOUp to $30M equity facility
Mitesco Files S-1 to Register Equity Line Shares
Nevada-incorporated Mitesco filed an S-1 to register shares issuable under a new equity line of credit, part of a small-cap financing pattern distinct from this week's AI mega-rounds.
BOA Acquisition Corp II Files for $200M Blank-Check IPO
IPO$200M target IPO
BOA Acquisition Corp II Files for $200M Blank-Check IPO
BOA Acquisition Corp II filed to raise up to $200 million in a blank-check IPO targeting real estate and infrastructure, part of a steady 2026 revival in SPAC issuance running well below the AI-mega-deal headlines.
Europe Posts Its Best VC Quarter in 4 Years as UK Leads
IPO$24B Q2 2026 European funding
Europe Posts Its Best VC Quarter in 4 Years as UK Leads
European startups raised $24 billion in Q2 2026, up two-thirds year-over-year, with UK startups alone pulling in more than $10 billion -- the region's third-largest quarter on record.
AEON Biopharma, Mobix Labs S-1 Filings Test a Thin Pipeline
IPO
AEON Biopharma, Mobix Labs S-1 Filings Test a Thin Pipeline
AEON Biopharma filed a fresh S-1 for a biosimilar program while Mobix Labs amended its filing disclosing a going-concern warning -- a reminder this week's IPO pipeline is mostly small-cap, not AI infrastructure.
Smith Micro Files Non-Dilutive S-1 for Warrant Shares
IPO
Smith Micro Files Non-Dilutive S-1 for Warrant Shares
Smith Micro Software filed a Form S-1 solely to register the resale of shares underlying previously issued warrants and convertible notes, explicitly stating the filing dilutes no existing shareholders.
This Week's Quiet IPO Calendar Is the Real Story
IPO
This Week's Quiet IPO Calendar Is the Real Story
Beyond SK Hynix's $28-29 billion Nasdaq debut, this week's US IPO calendar is nearly empty -- a sharp contrast to June's run of SpaceX, Cerebras and Lime, and a sign the pipeline is thinner than headline enthusiasm suggests.
SK Hynix Prices $28B Nasdaq Offering, 7x Oversubscribed
IPO~$28-29B raise, priced ~$158/ADS
SK Hynix Prices $28B Nasdaq Offering, 7x Oversubscribed
SK Hynix priced its Nasdaq ADS offering at roughly $158 per share on July 9 after a book that was reportedly oversubscribed 7 times, with trading set to begin July 10 under ticker SKHY.
Europe's Exit Engine Is Running on M&A, Not IPOs
IPO$7.2B M&A, Q2 2026
Europe's Exit Engine Is Running on M&A, Not IPOs
European startups exited $7.2 billion across 172 M&A deals in Q2 2026, with four of the 18 global $1 billion-plus VC-backed acquisitions coming from Europe -- while the region's IPO pipeline stays thin.
Anthropic's $50B Round Shows Why the IPO Pipeline Is Shrinking
IPO$50B Series H (May 2026)
Anthropic's $50B Round Shows Why the IPO Pipeline Is Shrinking
Anthropic's $50 billion Series H, split across a ten-investor syndicate plus separate multi-billion tranches from Google and Amazon, shows how mega private rounds are absorbing capital that once would have pushed companies toward an IPO.